Regulators Work On Global Biosimilar Extrapolation Rules, MAb Assessments
This article was originally published in SRA
Executive Summary
As part of its regulatory convergence effort, the International Pharmaceutical Regulators Forum is working on two projects intended to help align global requirements regarding the extrapolation of indications for biosimilar medicines and the assessment of biosimilar monoclonal antibodies (MAbs).